Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Products under Development by Stage of Development | 8 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Products under Development by Therapy Area | 9 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Products under Development by Indication | 10 | 2 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Products under Development by Companies | 14 | 3 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Companies Involved in Therapeutics Development | 22 | 10 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Enumeral Biomedical Holdings, Inc. | 23 | 1 |
| GlaxoSmithKline Plc | 24 | 1 |
| Incyte Corporation | 25 | 1 |
| MacroGenics, Inc. | 26 | 1 |
| Novartis AG | 27 | 1 |
| Regeneron Pharmaceuticals, Inc. | 28 | 1 |
| Sutro Biopharma, Inc. | 29 | 1 |
| Symphogen A/S | 30 | 1 |
| Tesaro, Inc. | 31 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Drug Profiles | 32 | 15 |
| BMS-986016 Drug Profile | 32 | 2 |
| ENUM-006 Drug Profile | 34 | 1 |
| GSK-2831781 Drug Profile | 35 | 1 |
| IMP-701 Drug Profile | 36 | 1 |
| IMP-731 Drug Profile | 37 | 1 |
| LAG-525 Drug Profile | 38 | 1 |
| MGD-013 Drug Profile | 39 | 1 |
| Monoclonal Antibody to Inhibit LAG-3 for Oncology Drug Profile | 40 | 1 |
| Monoclonal Antibody to Inhibit LAG-3 for Oncology Drug Profile | 41 | 1 |
| Monoclonal Antibody to Inhibit LAG3 for Oncology Drug Profile | 42 | 1 |
| Monoclonal Antibody to Inhibit LAG3 for Oncology Drug Profile | 43 | 1 |
| Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology Drug Profile | 44 | 1 |
| Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation Drug Profile | 45 | 1 |
| TSR-033 Drug Profile | 46 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Dormant Projects | 47 | 1 |
| Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) Featured News &Press Releases | 48 | 2 |
| Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016 | 48 | 1 |
| Jan 27, 2016: US Patent Grants for IMP731 Antibody | 48 | 1 |
| Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program | 48 | 1 |
| Jan 28, 2015: Prima BioMed to Receive Financial Milestone Payment From GSK | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |